NIH

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Retrieved on: 
Monday, March 25, 2024
ODD, Research, Food and Drug Administration, U.S. FDA, Drug discovery, AML, International, Patient, Committee, SBIR, Female, Acute myeloid leukemia, Sale, INN, Marker, EMA, OTS, NIH, IND, Myelodysplastic syndrome, European Medicines Agency, Counsel, Therapy, MRD, Bone marrow, USAN, MDS, APOLLO, FDA, DLBCL, Press release, CD19, Pharmaceutical industry

Marker also executed a comprehensive non-dilutive agreement with Cell Ready which included a sale of select cell manufacturing assets from Marker for approximately $19 million in cash.

Key Points: 
  • Marker also executed a comprehensive non-dilutive agreement with Cell Ready which included a sale of select cell manufacturing assets from Marker for approximately $19 million in cash.
  • Granted ODD from the Committee for Orphan Medicinal Products of the EMA for the treatment of patients with AML in 2023.
  • On June 26, 2023, Marker completed a non-dilutive transaction with Cell Ready, under which Cell Ready purchased certain cell manufacturing assets from Marker for approximately $19 million in cash.
  • Cash Position and Guidance: At December 31, 2023, Marker had cash and cash equivalents of $15.1 million.

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

Retrieved on: 
Tuesday, April 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Tobacco, Clinical Trials, Retail, Disease, Cardiovascular Research, Society, IND, Psychology, Therapy, Senior counsel, Population health, School, Dean (education), Partnership, Nicotine, Policy, Smoker, Behavior, NIH, Brown University, Trial of the century, University, SAB, Pharmacology, Homelessness, San Francisco General Hospital, UCSF, Public, Cancer, MD, Publication, Heated tobacco product, Hospital, Juul, FDA, Alpert Medical School, Pregnancy, Chair, Public health, University of Kansas, Cardiology, CTA, Mortality, Louisiana State University, Doctor of Philosophy, MHRA, Smoking, Toxicology, Division, Brown, Social science, Pharmaceutical industry

“We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.

Key Points: 
  • “We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.
  • Last fall, QN-01 demonstrated a superior pharmacokinetic profile compared to existing nicotine replacement therapies in our first-in-human Phase 1 clinical trial.
  • We plan to submit our IND and CTA to the regulatory bodies and look forward to commencing our Phase 1/2 clinical study this year.
  • He also served a three-year term on the Board of the Society for Research on Nicotine and Tobacco.

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Retrieved on: 
Monday, April 8, 2024
Research, Surgery, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, General Health, Science, Biopsy, Reward, Plasma, International Society, Cohort (statistics), Physician, Risk, AUC, Nucleic acid thermodynamics, Patient, Journal, DNA, Lung transplantation, Heart transplantation, MD, NIH, NTRA, Hospital, Molecule, Bangladesh Technical Education Board, Medicare, Oportunidades, Annual general meeting, NPV

“We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.

Key Points: 
  • “We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.
  • That study showed the Prospera Heart test had an overall area under the curve (AUC) of 0.86 for identifying acute rejection in over 800 samples from 200 adults with heart transplants.
  • The DTRT-2 (DNA-Based Transplant Rejection Test) study, published recently in Pediatric Transplantation , was sponsored by the National Institutes of Health (NIH).
  • A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients.

C2Sense® and Princeton BioMeditech Receive Second Award from NIH RADx® Tech High Performance Program for Digitally Connected, At-Home Diagnostic Reader and Multiplex COVID-19/Flu A&B Rapid Test

Retrieved on: 
Tuesday, April 9, 2024
Medical imaging, ACME, Halo, Human services, SARS-CoV-2, NIH, Acceleration, Clinical trial, National Institutes of Health, POC, BBC, Omicron, Biological engineering, Bangladesh Technical Education Board, Federal, Health department, PBM, Princeton University

The companies are currently planning their upcoming clinical trial, regulatory submission, and transfer to manufacture.

Key Points: 
  • The companies are currently planning their upcoming clinical trial, regulatory submission, and transfer to manufacture.
  • "After rigorous testing and intensive data collection, Halo®, used in conjunction with the PBM multiplex rapid test, continues to demonstrate outstanding sensitivity and reliability," said Jason Cox, Ph.D., CEO at C2Sense.
  • "Powered by our latest algorithm release, the price vs. performance of our Halo reader is unparalleled."
  • As always, we remain committed to providing our customers with the best possible solution for at-home testing," added Cox.

CURE OPENS XSEED AWARD APPLICATIONS TO SUPPORT UNDERFUNDED AND UNDERREPRESENTED NYC LIFE SCIENCE STARTUPS WITH UP TO $500,000

Retrieved on: 
Tuesday, April 9, 2024
Xchange, Pharmacology, Health, Mentorship, NYCEDC, Health equity, Research, Female, Doctor of Philosophy, Faculty, NIH, Male, Syneos Health, MPH, Pediatrics, Drug development, Economic development, Cure, Nursing

Deerfield Management, a New York City-based healthcare investment firm, founded and supports the XSeed Award.

Key Points: 
  • Deerfield Management, a New York City-based healthcare investment firm, founded and supports the XSeed Award.
  • The deadline for XSeed Award application submissions is May 31, 2024, and virtual finalist presentations will be June 28, 2024.
  • "Deerfield is pleased to continue our collaboration on the transformational XSeed program, alongside the NYCEDC, Cure and the experts who comprise our enthusiastic XSeed Award Leadership Committee."
  • "We look forward to welcoming the XSeed Award winners who, along with the Cure Xchange Challenge winners, are startups advancing health through collaboration and community building via Cure."

Solve M.E. Announces Emily Taylor as New President and CEO and Publication of New White Paper Calling for NIH to Restructure Funding for ME/CFS, Long Covid, and other IACCIs

Retrieved on: 
Monday, April 8, 2024
Engagement, STAT, Postural orthostatic tachycardia syndrome, The Washington Post, POTS, Patient, Public, COVID-19, Research, Black, Volunteering, NIH, News, Business News, ScienceDirect, PTLDS, M.E, Management

Emily has been a key member of Solve's leadership team for more than eight years and played a critical role in securing $1.25 billion RECOVER NIH funding for Long Covid research.

Key Points: 
  • Emily has been a key member of Solve's leadership team for more than eight years and played a critical role in securing $1.25 billion RECOVER NIH funding for Long Covid research.
  • Solve Board Chair John Nicols states, "We congratulate Emily and look forward to her leadership."
  • Solve also announces the publication of their newest white paper, co-authored by Emily, " A Home for Infection-Associated Chronic Conditions and Illnesses (IACCIs) at NIH ."
  • BIPOC (Black, Indigenous, and other People of Color), Latino/Latina, LGBTQIA+, and marginalized, underserved and economically disadvantaged populations are disproportionately impacted by IACCIs.

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

Retrieved on: 
Thursday, March 21, 2024
Glaucoma, B&L, Inflammation, Common, Telecanthus, NIH, CHRO, ISTA, Allergan, Pain, Therapy, Poultry farming

FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.

Key Points: 
  • FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.
  • The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications.
  • Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae.
  • “The launch of our eye pain treatment program represents a significant milestone for the Company.

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Retrieved on: 
Thursday, March 21, 2024
Stroke, Netherlands Cancer Institute, Conference, Development, Immunotherapy, GSK, Patient, Lung, DSM-IV codes, National Cancer Institute, MD Anderson Cancer Center, University, Doctor of Philosophy, NIH, Senior, Sarcoma, Clinical trial, Annual report, Bangladesh Technical Education Board, Squamous-cell carcinoma, OCCC, Pharmaceutical industry

PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100.

Key Points: 
  • -- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers --
    PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc .
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100.
  • The clinical trial was initiated by, and is being conducted at, the University of Texas MD Anderson Cancer Center.
  • Dr. Bernards is a member of the Board of Directors of LIXTE.

University of South Florida research funding reaches record high of $692 million

Retrieved on: 
Wednesday, March 20, 2024
Rhea, College, Health, Corps, Brain, Organization, Growth, Alzheimer's disease, National Science Foundation, University, Insomnia, Knowledge, Research, Sleep, Bird, Engineer, Chronic pain, AAAS, NIH, Water, USF, Bangladesh Technical Education Board, Spectrum, Disorder

“The University of South Florida's record-breaking success in research funding is a reflection of our commitment to advancing new knowledge, fostering innovation and making a positive impact on society," USF President Rhea Law said.

Key Points: 
  • “The University of South Florida's record-breaking success in research funding is a reflection of our commitment to advancing new knowledge, fostering innovation and making a positive impact on society," USF President Rhea Law said.
  • "The dedicated work of our world-class faculty, talented research staff and collaborative partners continues to lift USF’s research enterprise to new heights."
  • USF’s funding from private partnerships grew by 11% to $218 million, while funding from state and local sources nearly doubled to $82 million.
  • “This substantial increase in research enterprise funding reflects USF’s stature as a top public research university,” said Sylvia Wilson Thomas, USF vice president for research and innovation.

Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

Retrieved on: 
Wednesday, March 20, 2024
Research, Harvard Medical School, Massachusetts General Hospital, Nicotine, Smoker, NIH, Society, Smoking, Safety, Bangladesh Technical Education Board, Annual general meeting, Tobacco

March 21, 2024, 11:30 AM GMT: Achieve’s Director of Clinical Operations, Roxann Becco, will present patient-reported outcomes from the Phase 3 ORCA-2 and ORCA-3 clinical trials.

Key Points: 
  • March 21, 2024, 11:30 AM GMT: Achieve’s Director of Clinical Operations, Roxann Becco, will present patient-reported outcomes from the Phase 3 ORCA-2 and ORCA-3 clinical trials.
  • Data collected include trial participants’ experiences, such as cravings and withdrawal symptoms, personal impact on overall health, and opinions on future use.
  • ORCA-V1 evaluated the effectiveness and safety of cytisinicline in users of nicotine e-cigarettes who wanted to quit vaping.
  • The content is the sole responsibility of the authors and does not necessarily represent the official views of the NIH.